Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Ce...

por Li, Ying, Lu, Jia-Jing, Zhong, Xiao-Yuan, Yu, Ying-Yuan, Yu, Ning, Wang, Yu, Yi, Xue-Mei, Ding, Yang-Feng, Shi, Yu-Ling
Publicado 2022